반응식
Br[C:2]1[CH:23]=[CH:22][C:5]2[N:6]=[C:7]([NH:10][CH:11]3[C:19]4[C:14](=[CH:15][CH:16]=[CH:17][C:18]=4[O:20][CH3:21])[CH2:13][CH2:12]3)[O:8][CH2:9][C:4]=2[CH:3]=1.[C:24]([N:28]1[N:32]=[N:31][C:30]([NH2:33])=[N:29]1)([CH3:27])([CH3:26])[CH3:25]>>[C:24]([N:28]1[N:32]=[N:31][C:30]([NH:33][C:2]2[CH:23]=[CH:22][C:5]3[N:6]=[C:7]([NH:10][CH:11]4[C:19]5[C:14](=[CH:15][CH:16]=[CH:17][C:18]=5[O:20][CH3:21])[CH2:13][CH2:12]4)[O:8][CH2:9][C:4]=3[CH:3]=2)=[N:29]1)([CH3:27])([CH3:26])[CH3:25]참가 물질
3
실험 절차
The title compound (34 mg, 16%), off-white foam, MS (ISP): m/e=434.4 (M+H+), was prepared in accordance with the general method of Example 35 from rac-(6-bromo-4H-benzo[d][1,3]oxazin-2-yl)-(7-methoxy-indan-1-yl)-amine (Example 74) (187 mg, 0.5 mmol) and commercially available 2-tert.-butyl-2H-tetrazole-5-yl-amine (141 mg, 1.0 mmol).
출처 및 근거
- ORD 기록
- ord-fe12d32c6d7b46a3a0eb19a5cad97617
- 출처 데이터셋
- uspto-grants-2012_04
- 특허 번호
- US08163740B2
연결된 노트
불러오는 중…